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Nuno Rodrigues Faria1, Ester C. Sabino2, Marcio R. T. Nunes3,4, Luiz Carlos Junior Alcantara5,
Nicholas J. Loman6* and Oliver G. Pybus1Editorial summary
The World Health Organization has declared Zika virus
an international public health emergency. Knowledge
of Zika virus genomic epidemiology is currently
limited due to challenges in obtaining and processing
samples for sequencing. The ZiBRA project is a United
Kingdom–Brazil collaboration that aims to improve
this situation using new sequencing technologies.Background to the Zika epidemic
On 1 February 2016, the World Health Organization
declared a Public Health Emergency of International
Concern in response to the transmission of Zika virus
(ZIKV) in the Americas and beyond. Although ZIKV
was first isolated as early as 1947, only 13 naturally
occurring cases were identified in the six decades
following its discovery, in Nigeria, Malaysia, and
Indonesia [1]. The profile of the virus changed in 2007,
when an outbreak of ZIKV was reported in the Yap
islands, Micronesia, after which three-quarters of the
local population are estimated to have been infected
[1]. Between 2012 and 2014 the Asian genotype of
ZIKV spread through Southeast Asia and the Western
Pacific, before eventually reaching the Americas.
The first suspected cases of ZIKV infection in the
Americas were detected in Brazil in early March 2015 in
Natal (Rio Grande do Norte state) [2] and Camaçari
(Bahia state) [3]. These two cities in the northeast of
Brazil are located more than 1000 km apart. A year after
its first detection, a preliminary analysis of Brazilian
ZIKV genome sequences estimated that ZIKV reached
the Americas between May and December 2013, most
likely through a chance importation event that coincides* Correspondence: n.j.loman@bham.ac.uk
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from plausible source locations [4]. At the time of
writing, the Asian genotype of ZIKV has spread to 65
countries (Fig. 1) [5] and Brazil remains the country with
the highest cumulative number of cases. A growing, but
still incomplete, body of evidence points towards an as-
sociation between ZIKV infection and serious disease,
including microcephaly in newborns and Guillain–Barré
syndrome [6].Virus genomes in epidemiology
Viral molecular sequences can play an important role in
tackling emerging epidemics and were widely used to
understand the 2009 H1N1 influenza pandemic and the
spread of Ebola virus in West Africa in 2013–2016 (for
example, [7]). Sampled genomes enable us to quantify
viral genetic diversity, reconstruct epidemic origins,
estimate rates of transmission, and provide background
information for vaccine development and drug design.
Despite this, there is a paucity of complete genome se-
quences for ZIKV (Fig. 1). Until July 2016, only 23 ZIKV
genomes from Brazil were publically available, yet over
190,000 suspected Zika cases have been reported to the
Brazilian Ministry of Health since 2015. This equates to
just 1.2 ZIKV genome sequences per 10,000 suspected
infections. Consequently, we have only a fragmentary
picture of the diversity of ZIKV circulating in the country.
In comparison, the West African Ebola epidemic was
densely sampled and sequenced; in total, researchers gen-
erated full virus genomes for more than 5 % of all known
Ebola virus cases in West Africa between 2014 and 2016.
Detection of ZIKV cases in Brazil is complicated by the
co-circulation of Zika, dengue, and chikungunya viruses in
the country [8], the clinical symptoms of which overlap
with those of ZIKV, and by the fact that many Zika infec-
tions cause only mild disease and therefore go unreported.
Indeed, recent estimates of the true number of ZIKV cases
suggest there were 37.4 million infections during 2015
alone [9]. If true, this lowers the sampling proportion tole is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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Fig. 1 Number of whole virus genomes available for the Asian genotype of Zika virus present in the Americas and beyond. The bar plot shows
the cumulative number of Zika virus (ZIKV) genomes from each World Health Organization (WHO) geographic region (see key). The dashed black
line indicates the cumulative number of countries affected by the 2015–2016 ZIKV epidemic as of 14 July 2016 [5]. The red line indicates the
cumulative number of notified cases in Brazil according to the Brazilian Ministry of Health. An estimate of the sampling proportion (number of
ZIKV genomes from Brazil per 10,000 ZIKV notified cases in Brazil) is shown above each bar, from 2015 onwards. Dec December, Jun June
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Dearth of Zika virus genomes
Why are so few ZIKV genomes available more than a year
after the virus was discovered in the Americas? Data from
the Zika Open Research Portal (https://zika.labkey.com)
suggest that, in an animal model of infection, ZIKV viral
load reaches a maximum only 1–2 days after virus infec-
tion. Furthermore, in humans, it seems that viral load
peaks within a week of onset of clinical symptoms [1].
The early peak in viremia, combined with mild symptoms
for many ZIKV infections, means that there is often little
virus left for sequencing when clinical samples (usually
serum) are taken from patients with suspected ZIKV
infection. Consequently, it has proven comparatively
difficult to obtain full ZIKV genomes directly from clin-
ical material without enrichment (for example, http://
andersen-lab.com/zika-virus-pilot). Most commonly this
is undertaken by growth in cell culture, but this method
is laborious and has the potential to introduce culture-
specific genetic changes. An alternative approach is
genome-tiling PCR, a technique used to good effect on
Ebola virus but which requires labor-intensive protocol
development and testing for good results.In order to improve this situation we initiated a pilot
project—the Zika in Brazil Real-time Analysis (ZiBRA)
project—which aims to improve the molecular surveillance
and sequencing of ZIKV in Brazil through collaboration
and capacity building with a number of Brazilian research
groups and institutions. ZiBRA aims to share data and
results as soon as they are finished and updates are pro-
vided on the ZiBRA website (http://zibraproject.github.io).
The founding ZiBRA team comprised 16 members, 14 of
whom are from three Brazilian institutes: the University of
Sao Paulo, FioCruz Bahia, and the Instituto Evandro
Chagas. Further support has been provided by the
Ministry of Health in Brazil. The project officially
started in June 2016 and aims to address the following
four questions.
First, what is the extent of the genetic diversity of
ZIKV circulating in Brazil? This information is useful for
vaccine design and for improving existing molecular
diagnostic methods. Second, when and where was the
virus introduced in the country? Better estimates of the
dates of ZIKV introduction into each region will help
epidemiologists to correctly determine the pre-ZIKV
baseline level of microcephaly in each state. We will also
test the hypothesis that ZIKV arrived first in Brazil,
before spreading to other countries in the Americas [4].
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through Brazilian states and municipalities? We aim to
build retrospective and predictive models of virus spread
that will enable real-time tracking and forecasting of the
spread of arthropod-borne viruses in Brazil. Fourth, are
there associations between changes in the ZIKV genome
and the likelihood of ZIKV complications such as micro-
cephaly and Guillain–Barré? No such associations have
yet been found, but the hypothesis is sufficiently import-
ant to warrant careful monitoring.
Between 2 and 17 June 2016, the ZiBRA project under-
took fieldwork in a mobile laboratory that travelled across
five federal states in the Northeast region of Brazil. This
region was chosen because it contained locations with the
highest numbers of notified ZIKV cases and cases of
suspected microcephaly and congenital malformation.
During this fieldwork we used the MinION, an innovative
real-time portable genome sequencing device developed
by Oxford Nanopore, which had previously been success-
ful in characterizing the genomic diversity of Ebola virus
in Guinea [7]. In Brazil, the MinION was used to perform
portable whole-genome sequencing after tiling PCR.
Clinical diagnosis of suspected ZIKV cases in Brazil is
performed by local clinicians, who then send patient
samples (most commonly serum) to the local Central
Laboratory of Public Health (LACEN), usually located in
the capital city of each federal state, from where they are
sent to a reference laboratory for molecular confirmation
by PCR. However, during the ZiBRA fieldtrip, we found
that many samples sent by the LACENs were still await-
ing testing. Backlogs were caused by the unprecedented
scale of the Zika public health emergency and by the fact
that the laboratories must also cope with cases of sus-
pected chikungunya and dengue virus infection, viruses
that co-circulate in the same regions. Fast turnaround of
molecular diagnostic results is clearly needed; some
LACENs reported waiting 9 months between the date of
sample collection and delivery of diagnostic results.
Early results from the ZiBRA project
The ZiBRA team, with the help of LACEN personnel,
tested 1349 samples for ZIKV RNA across Rio Grande do
Norte, Paraíba, Recife, Maceió, and Bahia states, using
previously described protocols [10] and the Rotor-Gene Q
(Qiagen). Of these 1349 samples, approximately 14 % were
sampled in 2015 and 86 % in 2016. In addition, two ento-
mologists from Instituto Evandro Chagas, supported by
personnel from local LACENs and Municipal Health Sec-
retaries, captured more than 850 mosquitoes during the
field trip from seven different species across 19 geographic
locations. During the trip we trained all ZiBRA team
members to perform PCR and sequencing using the
Oxford Nanopore MinION platform and undertook se-
quencing of a set of samples. However, we found thatmost of the genomes generated during the fieldwork were
fragmentary, often having less than 50 % coverage. This is
likely due to the low amounts of virus in the samples.
More recently, we developed a second version of our mul-
tiplexed tiling PCR protocol, details of which are available
on the ZiBRA website (http://zibraproject.github.io). As
part of our commitment to open science practices, both
the protocol and materials are freely available through our
website in advance of formal publication. This open
analysis enables Zika research to move forward faster
internationally: weeks after publishing our multiplex PCR
protocol, Kristian Andersen’s laboratory at the Scripps
Research Institute adopted it for sequencing of clinical
samples from the United States. They rapidly modified
it to support the Illumina platform and subsequently
released their protocol openly for others to use (http://
andersen-lab.com/miseq-protocol-zika-virus-sequencing/).
Next steps
Complete genomic characterization of the ZIKV RNA-
positive samples identified by ZiBRA will provide a frame-
work for reconstructing the epidemic trajectories taken by
ZIKV in the Americas and for tracking its spread into
other geographic regions. We hope that ZiBRA will illus-
trate the practicality and benefits of open science and real-
time data sharing during a public health emergency.
Through our partnership with the Brazilian Ministry of
Health, we shared all PCR results with the LACENs within
48 hours of analysis. In the future, we and a growing net-
work of Brazilian scientists aim to extend the pilot ZiBRA
project to a national scale, in order to establish a Brazilian
surveillance network capable of detecting and characteriz-
ing a broad range of arboviruses in real-time.
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